Brookstone Capital Management Sells 233,448 Shares of Boston Scientific Corporation $BSX

Brookstone Capital Management reduced its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 93.3% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 16,783 shares of the medical equipment provider’s stock after selling 233,448 shares during the period. Brookstone Capital Management’s holdings in Boston Scientific were worth $716,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Boston Scientific by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock worth $13,319,060,000 after acquiring an additional 1,436,550 shares in the last quarter. State Street Corp lifted its position in Boston Scientific by 1.4% in the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after acquiring an additional 920,495 shares in the last quarter. Capital World Investors lifted its position in Boston Scientific by 1.9% in the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after acquiring an additional 502,627 shares in the last quarter. Norges Bank acquired a new position in Boston Scientific in the 4th quarter worth $2,199,395,000. Finally, Morgan Stanley increased its holdings in Boston Scientific by 10.8% during the 4th quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after purchasing an additional 2,246,308 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 0.4%

NYSE:BSX opened at $51.40 on Thursday. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The firm has a market capitalization of $74.49 billion, a price-to-earnings ratio of 20.81, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The stock’s 50 day moving average price is $45.94 and its two-hundred day moving average price is $59.69.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm’s revenue was up 7.5% on a year-over-year basis. During the same period last year, the business earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its board has authorized a share repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Wolfe Research downgraded Boston Scientific from an “outperform” rating to a “peer perform” rating in a research note on Friday, May 29th. TD Cowen reduced their price objective on Boston Scientific from $61.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Stifel Nicolaus set a $60.00 price objective on Boston Scientific in a report on Wednesday, July 29th. Piper Sandler reissued an “overweight” rating and issued a $65.00 target price on shares of Boston Scientific in a research report on Friday, June 12th. Finally, Barclays reduced their price target on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a research report on Thursday, May 28th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $71.62.

Insider Activity

In other news, Director Cheryl Pegus bought 1,770 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the purchase, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ? increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Michael F. Mahoney purchased 186,240 shares of Boston Scientific stock in a transaction that occurred on Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This trade represents a 13.27% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have bought 204,322 shares of company stock worth $9,939,221. 0.34% of the stock is owned by insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.